{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:25:01Z","timestamp":1780590301778,"version":"3.54.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>We performed a meta-analysis to evaluate the efficacy and safety of weekly long-acting growth hormone replacement therapy compared to daily growth hormone in children with short stature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature search up to April 2021 was performed and 11 studies included 1,232 children with short stature treated with growth hormone replacement therapy at the start of the study; 737 of them were using weekly long-acting growth hormone replacement therapy and 495 were using daily growth hormone. They were reporting relationships between the efficacy and safety of long-acting growth hormone replacement therapy and daily growth hormone in children with short stature. We calculated the odds ratio (OR), and mean difference (MD) with 95% confidence intervals (CIs) to assess the efficacy and safety of weekly long-acting growth hormone replacement therapy compared to daily growth hormone in children with short stature using the dichotomous or continuous method with a random or fixed-effect model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Long-acting growth hormone replacement therapy had significantly lower height standard deviation scores chronological age (MD, \u22120.10; 95% CI, \u22120.13 to \u22120.08, p &amp;lt;0.001), and insulin-like growth factor binding protein-3 (MD, \u22120.69; 95% CI, \u22121.09 to \u22120.30, p &amp;lt;0.001) compared to daily growth hormone in children with short stature.<\/jats:p><jats:p>However, growth hormone replacement therapy had no significantly difference in height velocity (MD, \u22120.09; 95% CI, \u22120.69\u20130.5, p = 0.76), height standard deviation scores bone age (MD, \u22120.04; 95% CI, \u22120.10\u20130.02, p = 0.16), insulin-like growth factor 1 standard deviation scores (MD, 0.26; 95% CI, \u22120.26\u20130.79, p = 0.33), and incidence of adverse events (OR, 1.16; 95% CI, 0.90\u20131.50, p = 0.25) compared to daily growth hormone in children with short stature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long-acting growth hormone replacement therapy had significantly lower height standard deviation scores chronological age, and insulin-like growth factor binding protein-3 compared to daily growth hormone in children with short stature. However, growth hormone replacement therapy had no significant difference in height velocity, height standard deviation scores bone age, insulin-like growth factor 1 standard deviation scores, and incidence of adverse events compared to daily growth hormone in children with short stature. Further studies are required to validate these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.726172","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:27:50Z","timestamp":1638365270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["RETRACTED: Effect of Weekly Long-Acting Growth Hormone Replacement Therapy Compared to Daily Growth Hormone on Children With Short Stature: A Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Liyan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congfu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-18-8-901","article-title":"Treatment of a Pituitary Dwarf With Human Growth Hormone","volume":"18","author":"Raben","year":"1958","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1651-2227.1986.tb10356.x","article-title":"Human Growth Hormone Produced With Recombinant DNA Technology: Development and Production","volume":"75","author":"Flodh","year":"1986","journal-title":"Acta Paediatrica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000316130","article-title":"Current Indications for Growth Hormone Therapy for Children and Adolescents","volume":"18","author":"Richmond","year":"2010","journal-title":"Curr Indications Growth Hormone Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD003264.pub3","article-title":"Growth Hormone for Children With Chronic Kidney Disease","volume":"2","author":"Hodson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","first-page":"1","article-title":"Clinical Effectiveness and Cost-Effectiveness of Growth Hormone in Adults in Relation to Impact on Quality of Life: A Systematic Review and Economic Evaluation","volume":"6","author":"Bryant","year":"2002","journal-title":"Health Technol Assess"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD003887","article-title":"Recombinant Growth Hormone in Children and Adolescents With Turner Syndrome","volume":"1","author":"Cave","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00166","article-title":"Growth Hormone\u2019s Links to Cancer","volume":"40","author":"Boguszewski","year":"2019","journal-title":"Endocr Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.3.1222","article-title":"Long-Term Effects of Continuous Subcutaneous Infusion Versus Daily Subcutaneous Injections of Growth Hormone (GH) on the Insulin-Like Growth Factor System, Insulin Sensitivity, Body Composition, and Bone and Lipoprotein Metabolism in GH-Deficient Adults","volume":"86","author":"Laursen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-6-1616","article-title":"Pulsatile Versus Continuous Intravenous Administration of Growth Hormone (GH) in GH-Deficient Patients: Effects on Circulating Insulin-Like Growth Factor-I and Metabolic Indices","volume":"70","author":"J\u00f8rgensen","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e16223","DOI":"10.1371\/journal.pone.0016223","article-title":"Non-Compliance With Growth Hormone Treatment in Children is Common and Impairs Linear Growth","volume":"6","author":"Cutfield","year":"2011","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.114249","article-title":"Monitoring of Concordance in Growth Hormone Therapy","volume":"93","author":"Kapoor","year":"2008","journal-title":"Arch Dis Childhood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302008000500024","article-title":"News Options and Preparations in Growth Hormone Therapy","volume":"52","author":"Aguiar-Oliveira","year":"2008","journal-title":"Arquivos Brasileiros Endocrinologia Metabologia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.12057.1","article-title":"Update on GH Therapy in Adults","volume":"6","author":"Boguszewski","year":"2017","journal-title":"F1000Research"},{"key":"B14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000439333","article-title":"Long-Acting Growth Hormone: An Update","volume":"30","author":"Saenger","year":"2016","journal-title":"Adv Ther Pediatr Endocrinol Diabetol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-16-0111","article-title":"Growth Hormone Research Society Perspective on the Development of Long-Acting Growth Hormone Preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2015.07.004","article-title":"Status of Long-Acting-Growth Hormone Preparations\u20142015","volume":"25","author":"H\u00f8ybye","year":"2015","journal-title":"Growth Hormone IGF Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0203","article-title":"The Rationale and Design of TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency","volume":"6","author":"Sprog\u00f8e","year":"2017","journal-title":"Endocr Connections"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000416","article-title":"The Current State of Long-Acting Growth Hormone Preparations for Growth Hormone Therapy","volume":"25","author":"Yuen","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-Analysis of Observational Studies in Epidemiology: A Proposal for Reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000388","article-title":"Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer\u2013related Mortality","volume":"41","author":"Gupta","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"B23","unstructured":"RoB 2: A Revised Cochrane Risk-of-Bias Tool for Randomized Trials2020"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0353","article-title":"FDG-PET\/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies","volume":"21","author":"Sheikhbahaei","year":"2016","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2234","article-title":"Three-Year Efficacy and Safety of LB03002, a Once-Weekly Sustained-Release Growth Hormone (GH) Preparation, in Prepubertal Children With GH Deficiency (GHD)","volume":"97","author":"P\u00e9ter","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0148","article-title":"Efficacy and Safety of LB03002, a Once-Weekly Sustained-Release Human GH for 12-Month Treatment in Korean Children With GH Deficiency","volume":"169","author":"Hwang","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2502","article-title":"24-Month Use of Once-Weekly GH, LB03002, in Prepubertal Children With GH Deficiency","volume":"99","author":"Khadilkar","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3547","article-title":"Long-Acting C-Terminal Peptide\u2013Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children","volume":"102","author":"Zelinska","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3776","article-title":"A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency","volume":"102","author":"Chatelain","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-16-0905","article-title":"Long-Acting PEGylated Recombinant Human Growth Hormone (Jintrolong) for Children With Growth Hormone Deficiency: Phase II and Phase III Multicenter, Randomized Studies","volume":"177","author":"Luo","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000489262","article-title":"Once-Weekly Administration of Sustained-Release Growth Hormone in Korean Prepubertal Children With Idiopathic Short Stature: A Randomized, Controlled Phase II Study","volume":"90","author":"Hwang","year":"2018","journal-title":"Hormone Res Paediatrics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/1438723","article-title":"Use of PEGylated Recombinant Human Growth Hormone in Chinese Children With Growth Hormone Deficiency: A 24-Month Follow-Up Study","volume":"2019","author":"Qiao","year":"2019","journal-title":"Int J Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial","volume":"105","author":"S\u00e4vendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","first-page":"1","article-title":"Lonapegsomatropin (TransCon hGH) in Children With Growth Hormone Deficiency: Efficacy and Safety of Up to 2 Years of Treatment","volume":"2021","author":"Maniatis","year":"2021","journal-title":"Presented at ENDO"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab030","article-title":"Development of a Predictive Enrichment Marker for Oral GH Secretagogue LUM-201 in Children With Growth Hormone Deficiency","volume":"5","author":"Bright","year":"2021","journal-title":"J Endocr Soc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1159\/000470842","article-title":"Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children","volume":"87","author":"Fisher","year":"2017","journal-title":"Hormone Res Paediatrics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13409","article-title":"Somapacitan, a Once-Weekly Reversible Albumin-Binding GH Derivative, in Children With GH Deficiency: A Randomized Dose-Escalation Trial","volume":"87","author":"Battelino","year":"2017","journal-title":"Clin Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0514","article-title":"Comparative Pharmacokinetics and Pharmacodynamics of a New Sustained-Release Growth Hormone (GH), LB03002, Versus Daily GH in Adults With GH Deficiency","volume":"91","author":"Bidlingmaier","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","first-page":"155","article-title":"Measurement of IGF-1, IGFBP-3 and Free IGF-1 Levels by ELISA in Growth Hormone (GH) Deficient Children Before and After GH Replacement","volume":"20","author":"Wacharasindhu","year":"2002","journal-title":"Asian Pacific J Allergy Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000452150","article-title":"Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Hormone Res Paediatrics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.7.620","article-title":"Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3","volume":"91","author":"Ma","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)10384-1","article-title":"Circulating Concentrations of Insulin-Like Growth Factor I and Risk of Breast Cancer","volume":"351","author":"Hankinson","year":"1998","journal-title":"Lancet"},{"key":"B44","article-title":"Evaluation of Glucose Metabolism in Children With Growth Hormone Deficiency During Long-Term Growth Hormone Treatment","volume":"69","author":"Witkowska-Sedek","year":"2018","journal-title":"J Physiol Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12020-019-01950-9","article-title":"Efficacy and Safety of Long-Acting Growth Hormone in Children With Short Stature: A Systematic Review and Meta-Analysis","volume":"65","author":"Yang","year":"2019","journal-title":"Endocrine"}],"updated-by":[{"DOI":"10.3389\/fendo.2023.1220345","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"record-id":"45677"},{"DOI":"10.3389\/fendo.2023.1220345","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.726172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:46:47Z","timestamp":1711536407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.726172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":45,"alternative-id":["10.3389\/fendo.2021.726172"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.726172","relation":{"retraction":[{"id-type":"doi","id":"10.3389\/fendo.2023.1220345","asserted-by":"object"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"article-number":"726172"}}